Presence of direct thrombin inhibitors can affect the results and interpretation of lupus anticoagulant testing

American Journal of Clinical Pathology

Volumn 124, Issue 4, 2005, Pages 586-593

  Genzen, Jonathan R ^a,c   Miller, Jonathan L ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiphospholipid antibody syndrome; Coumadin; Dilute Russell viper venom test; Direct thrombin inhibitor; Heparin; Lupus anticoagulant; Platelet neutralization procedure; Warfarin

Indexed keywords

ARGATROBAN; HEPARIN ANTAGONIST; LEPIRUDIN; LUPUS ANTICOAGULANT; THROMBIN INHIBITOR; VIPER VENOM;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING PARAMETERS; CALCULATION; CONTROLLED STUDY; DIAGNOSTIC ERROR; DILUTE RUSSEL VIPER VENOM TIME; HUMAN; PARTIAL THROMBOPLASTIN TIME; PLASMA; PRIORITY JOURNAL; THROMBOCYTE;

EID: 25844489038     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/7RYUN5DRK4WCH3PM     Document Type: Article

References (28)

1. Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost. 2001;86:83-91.
2. Espinosa G, Cervera R, Font J, et al. Antiphospholipid syndrome: pathogenic mechanisms. Autoimmun Rev. 2003;2:86-93.
3. Wisloff F, Jacobsen EM, Liestol S. Laboratory diagnosis of the antiphospholipid syndrome. Thromb Res. 2002;108:263-271.
4. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309-1311.
5. Bevers EM, Galli M, Barbui T, et al. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost. 1991;66:629-632.
6. McNeil HP, Simpson RJ, Chesterman CN, et al. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87:4120-4124.
7. Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemost Thromb. 1972;1:75-95.
8. Greaves M, Cohen H, MacHin SJ, et al. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol. 2000;109:704-715.
9. Exner T, Triplett DA, Tabemer D, et al, for the SSC Subcommittee for the Standardization of Lupus Anticoagulants. Guidelines for testing and revised criteria for lupus anticoagulants. Thromb Haemost. 1991;65:320-322.
10. Machin S, Giddings J, Greaves M, et al. Guidelines on testing for the lupus anticoagulant. J Clin Pathol. 1991;44:885-889.
11. Brandt JT, Triplett DA, Alving B, et al, for the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost. 1995;74:1185-1190.
12. Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827-1832.
13. Schulman S. Clinical practice: care of patients receiving long-term anticoagulant therapy. N Engl J Med. 2003;349:675-683.
14. Meroni PL, Moia M, Derksen RH, et al. Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis. Lupus. 2003;12:504-507.
15. Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood. 1986;68:869-874.
16. Jacobsen EM, Trettenes EJ, Strekerud FG, et al. Lupus anticoagulant quantification in heparinized patients using addition of polybrene [abstract]. Lupus. 2002;11:591.
17. Triplett DA, Brandt JT, Kaczor D, et al. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol. 1983;79:678-682.
18. LA Screen/LA Confirm [package insert]. Hawthorne, NY: Gradipore; 2000.
19. Jouhikainen T. Detection of lupus anticoagulant by means of dilute Russell's viper venom time is affected by oral anticoagulant therapy. Blood Coagul Fibrinolysis. 1990;1:627-632.
20. Tripodi A, Chantarangkul V, Clerici M, et al. Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment: performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA. Thromb Haemost. 2002;88:583-586.
21. Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb Res. 2002;106:V275-V284.
22. Laposata M, Green D, Van Cott EM, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med. 1998;122:799-807.
23. Gosselin RC, King JH, Janatpur KA, et al. Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing. Arch Pathol Lab Med. 2004;128:1142-1145.
24. Genzen JR, Miller JL. Lupus anticoagulant testing in the presence of direct thrombin inhibitors [abstract]. Am J Clin Pathol. 2004;122:463. Abstract 35.
25. Bergstrom DA, Ferrell C, Chandler W. The effect of anticoagulant therapy on a partial thromboplastin time-based lupus inhibitor assay [abstract]. Am J Clin Pathol. 2004;122:461. Abstract 28.
26. National Committee for Clinical Laboratory Standards. Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays; Approved Guideline, 4th ed. H21-A4. Wayne, PA: NCCLS; 2003.
27. Schleider MA, Nachman RL, Jaffe EA, et al. A clinical study of the lupus anticoagulant. Blood. 1976;48:499-509.
28. Gustafsson D. Oral direct thrombin inhibitors in clinical development. J Intern Med. 2003;254:322-334.